Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 8, Pages e002279
Publisher
BMJ
Online
2021-08-26
DOI
10.1136/jitc-2020-002279
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy
- (2021) Guillermo O. Rangel Rivera et al. Frontiers in Immunology
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
- (2019) Yosuke Togashi et al. Nature Reviews Clinical Oncology
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
- (2019) Stalin Chellappa et al. JOURNAL OF IMMUNOLOGY
- Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids
- (2019) Akihiro Tokunaga et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
- (2019) Atsushi Tanaka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The function and dysfunction of memory CD8+ T cells in tumor immunity
- (2018) James L. Reading et al. IMMUNOLOGICAL REVIEWS
- PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
- (2018) Larissa S. Carnevalli et al. Journal for ImmunoTherapy of Cancer
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- (2017) Frederick Arce Vargas et al. IMMUNITY
- Effector CD8 T cells dedifferentiate into long-lived memory cells
- (2017) Ben Youngblood et al. NATURE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K and PI3K , Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
- (2016) K. Hudson et al. MOLECULAR CANCER THERAPEUTICS
- CD8 + T Lymphocyte Self-Renewal during Effector Cell Determination
- (2016) Wen-Hsuan W. Lin et al. Cell Reports
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
- (2015) Alexander M. Lesokhin et al. Science Translational Medicine
- Glucose Metabolism Regulates T Cell Activation, Differentiation, and Functions
- (2015) Clovis S. Palmer et al. Frontiers in Immunology
- Regulatory T cells in cancer immunotherapy
- (2014) Hiroyoshi Nishikawa et al. CURRENT OPINION IN IMMUNOLOGY
- Abstract B271: A first-in-human Phase I study of ZSTK474, an oral pan-PI3K inhibitor, in patients with advanced solid malignancies.
- (2014) A. C. Lockhart et al. MOLECULAR CANCER THERAPEUTICS
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- Molecular regulation of effector and memory T cell differentiation
- (2014) John T Chang et al. NATURE IMMUNOLOGY
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
- (2013) D. Sugiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of PI3K/Akt signaling in memory CD8 T cell differentiation
- (2013) Eui Ho Kim et al. Frontiers in Immunology
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations
- (2010) Shingo Dan et al. CANCER RESEARCH
- Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39
- (2010) Dexin Kong et al. EUROPEAN JOURNAL OF CANCER
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Complete but curtailed T-cell response to very low-affinity antigen
- (2009) Dietmar Zehn et al. NATURE
- Different T Cell Receptor Signals Determine CD8+ Memory Versus Effector Development
- (2009) E. Teixeiro et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started